Jones JA, et al. - The activity and safety of venetoclax were comprehensively analyzed during this study, in patients with chronic lymphocytic leukaemia who were refractory to or relapsed during or after ibrutinib therapy. Durable clinical activity and favourable tolerability were illustrated by venetoclax in the study cohort whose disease progressed during or after the discontinutation of ibrutinib therapy.